![Sriram Ryali](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sriram Ryali
Finanzdirektor/CFO bei
CARIBOU BIOSCIENCES, INC.
Vermögen: 30 554 $ am 30.06.2026
Profil
Sriram Ryali is Chief Financial & Accounting Officer at Caribou Biosciences, Inc. since 2025.
Former roles include Chief Financial & Accounting Officer at Codexis, Inc. from 2023 to 2024, Chief Financial Officer at Eiger BioPharmaceuticals, Inc. from 2018 to 2023, Vice President-Finance at Aimmune Therapeutics, Inc. from 2017 to 2018, Head-Medical Affairs, Technical Operations, R&D at Onyx Pharmaceuticals, Inc. from 2013 to 2015, and Senior Director-Financial Planning & Analysis at Jazz Pharmaceuticals Plc.
Education includes undergraduate studies at the University of California, Los Angeles and an MBA from UCLA Anderson School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 20.04.2026 | 17’360 ( 0.02% ) | 30 554 $ | 30.06.2026 |
Aktive Positionen von Sriram Ryali
| Unternehmen | Position | Beginn |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Finanzdirektor/CFO | 02.01.2025 |
Ehemalige bekannte Positionen von Sriram Ryali
| Unternehmen | Position | Ende |
|---|---|---|
| CODEXIS, INC. | Finanzdirektor/CFO | 30.09.2024 |
| EIGER BIOPHARMACEUTICALS | Finanzdirektor/CFO | 20.01.2023 |
| AIMMUNE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.12.2018 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2015 |
| JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | - |
Ausbildung von Sriram Ryali
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
47
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
Caribou Biosciences, Inc.
 Caribou Biosciences, Inc. BiotechnologyHealth Technology Develops technology-based solutions for cellular engineering and analysis | Health Technology |
University of California, Los Angeles
 University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Jazz Pharmaceuticals Plc
 Jazz Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of pharmaceutical products to treat neurological disorders | Health Technology |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of desensitization treatments for peanut and food allergies | Health Technology |
UCLA Anderson School of Management
 UCLA Anderson School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eiger BioPharmaceuticals, Inc.
 Eiger BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat and cure hepatitis delta virus and other serious diseases | Health Technology |
